The estimated Net Worth of Ventures Iv, L.P.5 Am Co In... is at least $1.07 Million dollars as of 7 October 2019. Ventures In owns over 333,333 units of Aprea Therapeutics stock worth over $1,073,332 and over the last 5 years Ventures sold APRE stock worth over $0.
Ventures has made over 1 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Ventures bought 333,333 units of APRE stock worth $4,999,995 on 7 October 2019.
The largest trade Ventures's ever made was buying 333,333 units of Aprea Therapeutics stock on 7 October 2019 worth over $4,999,995. On average, Ventures trades about 333,333 units every 0 days since 2019. As of 7 October 2019 Ventures still owns at least 333,333 units of Aprea Therapeutics stock.
You can see the complete history of Ventures In stock trades at the bottom of the page.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant..., and John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: